Emerg Infect Dis
. 2020 Jul 1;26(10).
doi: 10.3201/eid2610.201816. Online ahead of print.
COVID-19 in Patient With Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Fran?ois B?n?zit, Audrey Le Bot, St?phane Jouneau, Florian Lema?tre, Charlotte Pronier, Pierre-Axel Lentz, Sol?ne Patrat-Delon, Matthieu Revest, Vincent Thibault, Pierre Tattevin
- PMID: 32609083
- DOI: 10.3201/eid2610.201816
Abstract
Because of in vitro studies, hydroxychloroquine is under evaluation as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment, despite adequate plasma concentrations.
Keywords: 2019 novel coronavirus disease; COVID-19; France; SARS-CoV-2; coronavirus; coronavirus disease; hydroxychloroquine; plasma concentration; respiratory infections; sarcoidosis; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.